medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-3-2-104-110medsovet-970Research ArticleЭндокринологияEndocrinologyРезультаты и перспективы применения ингибитора ДПП-4 у больных сахарным диабетом 2-го типаResults and prospects for the use of DPP-4 inhibitor in patients with diabetes mellitus type 2МкртумянА. М.MkrtumianA. M.noemail@neicon.ruПодачинаС. В.PodachinaS. V.noemail@neicon.ruСвиридоваМ. А.SviridovaM. A.noemail@neicon.ruКанаузовМ. Я.KanauzovM. Ya.noemail@neicon.ruМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovRussian FederationПоликлиника Минэкономразвития РоссииРоссияPolyclinic of the Russian Ministry of Economic DevelopmentRussian Federation20133012201303-2104110Copyright © Мкртумян А.М., Подачина С.В., Свиридова М.А., Канаузов М.Я., 20132013Мкртумян А.М., Подачина С.В., Свиридова М.А., Канаузов М.Я.Mkrtumian A.M., Podachina S.V., Sviridova M.A., Kanauzov M.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/970

Заболеваемость сахарным диабетом во всем мире ежегодно увеличивается, несмотря на все усилия, предпринимаемые мировой медициной. Основной причиной инвалидизации и смертности больных сахарным диабетом 2-го типа по-прежнему остаются сердечно-сосудистые осложнения.

The incidence of diabetes worldwide is increasing annually, despite all efforts of the global healthcare. Cardiovascular complications remain the main cause of morbidity and mortality in patients with diabetes mellitus type 2.

сахарный диабет 2-го типасахароснижающие препаратыситаглиптинdiabetes mellitus type 2hypoglycemic agentsSitagliptinReferencesU.K. prospective diabetes study. Overwiew of 6 years therapy of type 2 diabetes: a progressive disease. U.K. Prospective diabetes study Group // Diabetes. 1995. №44. P. 1249–1258.U.K. prospective diabetes study. Overwiew of 6 years therapy of type 2 diabetes: a progressive disease. U.K. Prospective diabetes study Group // Diabetes. 1995. №44. P. 1249–1258.Viberty G., Kahn S.E., Greens D.A. et al. A diabetes outcome progression trial (ADOPT). An international multicenter study of the comparative efficacy of rosiglitasone,glyburide and metformin in recently diagnosed type 2 diabets // Diabets Care. 2002. №25. P. 1737–1743.Viberty G., Kahn S.E., Greens D.A. et al. A diabetes outcome progression trial (ADOPT). An international multicenter study of the comparative efficacy of rosiglitasone,glyburide and metformin in recently diagnosed type 2 diabets // Diabets Care. 2002. №25. P. 1737–1743.Holst J. The physiology and pharmacology of incretins in type 2 diabetes // Diabetes Obes. Metab. 2008. №10. Р. 14–21.Holst J. The physiology and pharmacology of incretins in type 2 diabetes // Diabetes Obes. Metab. 2008. №10. Р. 14–21.Garber A. Glucagon-like peptide-1-based therapies: new developments and emerging data // Journal Complication 2008 Blackwell Publishing Ltd Diabetas, Obesity and Metabolism. №10. P. 22–35.Garber A. Glucagon-like peptide-1-based therapies: new developments and emerging data // Journal Complication 2008 Blackwell Publishing Ltd Diabetas, Obesity and Metabolism. №10. P. 22–35.Hansen L., Deacon C., Orscov S. et al. Glucagon-like peptide-1 (7-36) amide is transformed to glucagon – like peptide-1 (9-36) amide by dipeptidyl peptidase IY in the capillaries sypplying the L-cells of the intestine // Endocrinology. 1999. №140. P. 5356–5363.Hansen L., Deacon C., Orscov S. et al. Glucagon-like peptide-1 (7-36) amide is transformed to glucagon – like peptide-1 (9-36) amide by dipeptidyl peptidase IY in the capillaries sypplying the L-cells of the intestine // Endocrinology. 1999. №140. P. 5356–5363.Goldstein B.J. et al. Effect of initial Combination Therapy With Sitaglipin, a Dipeptidy Peptidase-4 Ingibitor,and Metformin on glicemic control in Patients With Type 2 Diabetes // Diabetes Care. 2007. P. 1979–1987.Goldstein B.J. et al. Effect of initial Combination Therapy With Sitaglipin, a Dipeptidy Peptidase-4 Ingibitor,and Metformin on glicemic control in Patients With Type 2 Diabetes // Diabetes Care. 2007. P. 1979–1987.Scott RS et al. Poster presented at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD), Athens, Greece, September 12–15, 2005.Scott RS et al. Poster presented at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD), Athens, Greece, September 12–15, 2005.Qi DS., et al. Two year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycemic control in patients with type 2 diabetes. EASD Abstract August, 2008.Qi DS., et al. Two year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycemic control in patients with type 2 diabetes. EASD Abstract August, 2008.Романцова Т.И. Ингибитор дипептидилпептидазы– 4–ситаглиптин: новые возможности терапии сахарного диабета 2 типа // Ожирение и метаболизм. 2006. №4(9).Романцова Т.И. Ингибитор дипептидилпептидазы– 4–ситаглиптин: новые возможности терапии сахарного диабета 2 типа // Ожирение и метаболизм. 2006. №4(9).Little R.R., Tennil A.L., Rohlfing C., Wiedmeyer H.M., Khanna R., Goel S. Agrawal A. Madsen R, Goldstein D.E. Can glicohemoglobin be used to assess glycaemic control in patient with chronic renal failure? // Clin. Chem. 2002. May. №48(5). Р. 784–786.Little R.R., Tennil A.L., Rohlfing C., Wiedmeyer H.M., Khanna R., Goel S. Agrawal A. Madsen R, Goldstein D.E. Can glicohemoglobin be used to assess glycaemic control in patient with chronic renal failure? // Clin. Chem. 2002. May. №48(5). Р. 784–786.Chan J.C., Scott R., Arjona Ferreira J.C., Sheng D., Gonzales E., Davies M.J., Stein P.P., Kaufman K.D., Amatruda J.M., Williams-Herman D. Safety and efficasy of sitagliptin in patients with type 2 diabetes and chronic renal in sufficiency // Diabetes Obes. Metab. 2008. Jul. №10(7). Р. 545–555. Epub. 2008 Jun. 1.Chan J.C., Scott R., Arjona Ferreira J.C., Sheng D., Gonzales E., Davies M.J., Stein P.P., Kaufman K.D., Amatruda J.M., Williams-Herman D. Safety and efficasy of sitagliptin in patients with type 2 diabetes and chronic renal in sufficiency // Diabetes Obes. Metab. 2008. Jul. №10(7). Р. 545–555. Epub. 2008 Jun. 1.Ferreira L., Teixeira-de-la-Lemos E., Pinto F., Parda B., Mega C., Vala H., Pinto R., Garrido P., Sereno J., Fernandes R., Santos P., Velada I., Melo A., Nuns S., Teixeira F., Reis F. Effect of sitagliptin treatment on dysmetabolism, Inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) // Mediators Inflamm. 2010. 2010. 592760. Epub. 2010 Jun. 21.Ferreira L., Teixeira-de-la-Lemos E., Pinto F., Parda B., Mega C., Vala H., Pinto R., Garrido P., Sereno J., Fernandes R., Santos P., Velada I., Melo A., Nuns S., Teixeira F., Reis F. Effect of sitagliptin treatment on dysmetabolism, Inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) // Mediators Inflamm. 2010. 2010. 592760. Epub. 2010 Jun. 21.Yan S., Marguet D., Dobers J., et al. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen // Eur. J. Immunol. 2003. №33. Р. 1519–1527.Yan S., Marguet D., Dobers J., et al. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen // Eur. J. Immunol. 2003. №33. Р. 1519–1527.Wey U., Mojson S. Tissue-specific expression of the human receptor for glucagon-like peptide: brain, heart and pancreatic forms have the same deduced amino acid sequences // FEBS Left. 1995. №358. Р. 219–224.Wey U., Mojson S. Tissue-specific expression of the human receptor for glucagon-like peptide: brain, heart and pancreatic forms have the same deduced amino acid sequences // FEBS Left. 1995. №358. Р. 219–224.Bosi E. Time for testing incretin therapies in early type 1 diabetes? // Endocrinol. Metab. 2010. №95. Р. 2607–2609.Bosi E. Time for testing incretin therapies in early type 1 diabetes? // Endocrinol. Metab. 2010. №95. Р. 2607–2609.Gomes N., Touihri K., Matheeussen V. et al. Dipeptidylpeptidase IY inhibition improves cardiorenal function in overpacing-induced heart failure // Eur. J. Heart Fail. 2012. №14(1). Р. 14–21.Gomes N., Touihri K., Matheeussen V. et al. Dipeptidylpeptidase IY inhibition improves cardiorenal function in overpacing-induced heart failure // Eur. J. Heart Fail. 2012. №14(1). Р. 14–21.Read P.A., Khan F.Z., Heck P.M. et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery desease // Circulat. Cardiovasc. Imag. 2010. №3(2). Р. 195–201.Read P.A., Khan F.Z., Heck P.M. et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery desease // Circulat. Cardiovasc. Imag. 2010. №3(2). Р. 195–201.Мкртумян А.М. Гормоны-инкретины в регуляции секреции инсулина и перспективы применения ГПП-1 и ингибиторов ДПП-4 в лечении сахарного диабета типа 2 // В-клетка: секреция инсулина в норме и патологии 2009. С. 135–152.Мкртумян А.М. Гормоны-инкретины в регуляции секреции инсулина и перспективы применения ГПП-1 и ингибиторов ДПП-4 в лечении сахарного диабета типа 2 // В-клетка: секреция инсулина в норме и патологии 2009. С. 135–152.Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. М.: ГЭОТАР-Медиа, 2012. Гл. 13. С. 332–346.Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. М.: ГЭОТАР-Медиа, 2012. Гл. 13. С. 332–346.Arechavaleta R., Seck T., Chen Y. et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial // Diabetes Obes. Metab. 2011. №13(2). Р. 160–168.Arechavaleta R., Seck T., Chen Y. et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial // Diabetes Obes. Metab. 2011. №13(2). Р. 160–168.Seck T., Nauck M., Sheng D. et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study // Int. J. Clin. Pract. 2010. №64(5). Р. 562–576.Seck T., Nauck M., Sheng D. et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study // Int. J. Clin. Pract. 2010. №64(5). Р. 562–576.

The authors declare that there are no conflicts of interest present.